Trending Articles

article thumbnail

Biotech startups face ‘Series A cliff’ as venture capital stays cautious

Bio Pharma Dive

Series A rounds have been easy to secure in the last few years, but industry watchers say they haven't seen a corresponding increase in Series B's as startups struggle to recruit new investors

274
274
article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. It was a money-saving strategy that was paying off until Covid-19 hit.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders

Bio Pharma Dive

Armed with a $50 million Series A round, the startup is building off of research from a lab run by protein engineering pioneer Jim Wells

Protein 353
article thumbnail

HP&M Attorney Mark Tobolowsky Co-Authors Article in Human Gene Therapy Advocating for the Acceptance of Microdystrophin Expression in DMD Patients as a Surrogate Endpoint for Accelerated Approval

FDA Law Blog

Hyman, Phelps & McNamara, P.C.’s s Mark Tobolowsky co-authored the peer-reviewed article “ Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials ” in the recently published edition of Human Gene Therapy.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

article thumbnail

AbbVie's blockbuster-to-be Parkinson's combo hits a wall as FDA questions delivery pump

Fierce Pharma

AbbVie's blockbuster-to-be Parkinson's combo hits a wall as FDA questions delivery pump aliu Wed, 03/22/2023 - 11:17

121
121
article thumbnail

Recommendation from NICE for PTC Therapeutics gene therapy

Pharma Times

Eladocagene exuparvovec is for children with ultra-rare genetic disorder in final draft guidance

Genetics 115

More Trending

article thumbnail

The Rise, Fall and Future of Novavax

BioSpace

The Rise, Fall and Future of Novavax 3/21/2023

105
105
article thumbnail

Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD

Fierce Pharma

Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD kdunleavy Thu, 03/23/2023 - 01:37

Trials 116
article thumbnail

ABPI responds to rebooted MHRA clinical trials framework

Pharma Times

Measures include a requirement to publicly register studies and share results among research participants

article thumbnail

Sanofi, Regeneron surge as Dupixent scores in COPD trial

Bio Pharma Dive

The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines

Antibody 283
article thumbnail

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

article thumbnail

BioNTech and OncoC4 sign deal to co-develop antibody for solid tumours

Pharmaceutical Technology

BioNTech has signed an exclusive worldwide licence and collaboration agreement with OncoC4 to co-develop and commercialise a new checkpoint antibody in multiple solid tumour indications.

Antibody 242
article thumbnail

Samsung Biologics to start construction of Plant 5

BioPharma Reporter

Samsung Biologics will begin construction of Plant 5 within the first half of this year: marking the first facility for its second Bio Campus. Upstream Processing

98
article thumbnail

After appeals loss, Johnson & Johnson will take Texas two-step case to the US Supreme Court

Fierce Pharma

After appeals loss, Johnson & Johnson will take Texas two-step case to the US Supreme Court kdunleavy Wed, 03/22/2023 - 14:39

104
104
article thumbnail

Genedrive’s MT-RNR1 test achieves roll out in Greater Manchester

Pharma Times

Company will also operate work on particular initiatives across an additional five neonatal sites

116
116
article thumbnail

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

article thumbnail

Novo partners with Dewpoint to mine an emerging field for new drugs

Bio Pharma Dive

The companies will collaborate to identify compounds that could treat insulin resistance by targeting shape-shifting cellular droplets known as biomolecular condensates

Insulin 284
article thumbnail

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines.

Allergies 237
article thumbnail

Gilead’s Yescarta Bests Long-Time Standard of Care in R/R LBCL Overall Survival

BioSpace

Gilead’s Yescarta Bests Long-Time Standard of Care in R/R LBCL Overall Survival 3/22/2023

94
article thumbnail

AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda

Fierce Pharma

AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda aliu Thu, 03/23/2023 - 10:23

86
article thumbnail

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

article thumbnail

Evgen reveals results from pivotal phase 1b trial

Pharma Times

Study involves SFX-01 candidate and emerging preliminary pharmacokinetic data from study

Trials 105
article thumbnail

Moderna CEO defends price of COVID shot at Senate hearing

Bio Pharma Dive

Stéphane Bancel said his company's planned price hike covers the higher costs of commercial sales. Bernie Sanders called it part of industry’s “unprecedented level of corporate greed &rdquo

Sales 260
article thumbnail

The new frontiers of pharmaceutical innovation – according to investors ?

Pharmaceutical Technology

Pharma companies and world health stand to benefit from new technologies, but it’s a tough time to be an investor – and an even tougher one for firms seeking investment. From close to zero, central bank interest rates have risen to 3% in the Eurozone, 4% in the UK and nearly 5% in the USA.

Genome 225
article thumbnail

FDA Adcomm Backs Accelerated Approval of Biogen’s Tofersen in SOD1-ALS

BioSpace

FDA Adcomm Backs Accelerated Approval of Biogen’s Tofersen in SOD1-ALS 3/23/2023

90
article thumbnail

Eli Lilly CEO racked up $21.4M in 2022 pay as stock price hit all-time high

Fierce Pharma

Eli Lilly CEO racked up $21.4M in 2022 pay as stock price hit all-time high aliu Mon, 03/20/2023 - 10:51

94
article thumbnail

Astellas and Pfizer reveal positive results for Xtandi

Pharma Times

Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer

Trials 105
article thumbnail

Karuna’s schizophrenia drug succeeds in a second late-stage trial

Bio Pharma Dive

The results add to a growing body of evidence that Karuna’s drug, known as KarXT, could be a valuable new option for patients living with the brain disorder

Trials 273
article thumbnail

Cannabidiol milling: Selecting the right equipment for CBD testing

Pharmaceutical Technology

Cannabidiol is the second most prevalent active ingredient in cannabis (marijuana) and for medical purposes it is derived directly from the hemp plant (which is closely related to marijuana) or made in a laboratory.

article thumbnail

FDA Releases Briefing Docs for Upcoming Biogen/Ionis Tofersen Adcomm

BioSpace

FDA Releases Briefing Docs for Upcoming Biogen/Ionis Tofersen Adcomm 3/20/2023

96
article thumbnail

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst

Fierce Pharma

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst kdunleavy Fri, 03/24/2023 - 07:30

Sales 81
article thumbnail

Vitestro raises vital funding for autonomous blood drawing device

Pharma Times

Company raises €12m in financing with a view to entering to the European market

Marketing 104
article thumbnail

U.S. government again rejects call to seize Xtandi rights

Bio Pharma Dive

The Biden administration plans to review federal “march-in” rights and consider whether price could be a reason to take control of patents for drugs developed with government funding

Drugs 253
article thumbnail

Pfizer acquires ADC pioneer Seagen for $43bn

Pharmaceutical Technology

Pfizer recently announced an agreement to acquire Seagen, a biotech company based in the US with four marketed oncology therapeutic agents and a rich pipeline.

Licensing 147
article thumbnail

Webinars that Target a Global Audience Are Booming — What It Takes To Make The Most Of Them

XTalks

It’s without question that webinars have become the go-to marketing tool for organizations looking to grow their global footprint. Take Frost & Sullivan’s data for reference, the market for webinars and virtual events is anticipated to reach $4.44 billion in 2025 — up from $1.57

article thumbnail

US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi

Fierce Pharma

US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi fkansteiner Wed, 03/22/2023 - 09:50

86